One of the most challenging aspects of the COVID-19 pandemic was not being able to assess how individual patients would respond to the virus and how severe their symptoms would be.
Despite previously calling the UK a ‘very unattractive’ place to do business, AstraZeneca CEO Pascal Soriot is injecting £650 million into the UK life sciences industry.
Swedish-based company Empros Pharma has announced positive topline data from its phase 2b trial investigating EMP16, an oral therapy for the treatment of obesity.
Biotech company Transgene, IT solutions provider NEC, and biomedical software company BostonGene have expanded their collaboration for the phase 1/2 trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.
Form Bio and Ginkgo Bioworkshave joined forces in what they call a groundbreaking partnership aimed at advancing AAV gene therapy design and development.
Biogen’s stance at the upcoming AD/PD 2024 International Conference on Alzheimer’s disease and Parkinson’s disease will demonstrate its future plans for treating Alzheimer’s, following the discontinuation of Aduhelm (aducanumab), its anti-amyloid beta...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently refused marketing authorization for Nezglyal (leriglitazone).
OneChain Immunotherapeutics has received €1.9m from the Spanish Ministry of Science and Innovation to advance a ‘groundbreaking’ CAR-T therapy for acute lymphoblastic leukemia type T into clinical development.
Finnish health technology company Solu has launched an online tool to analyse and prevent outbreaks of Candida auris disease, which it claims is the fastest on the market.
Allecra Therapeutics, a biopharma company developing novel therapies to combat antibiotic resistance, has received FDA approval for its treatment tackling ‘complicated’ urinary tract infections (UTIs).
Curve Therapeutics, a biotech developing an intracellular screening platform addressing complex disease targets, has closed its £40.5 million Series A financing.
Baseimmune, a biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines, has closed its $11.3 million Series A funding round.
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the first launch of BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple...
The Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Janssen’s CARVYKTI (cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM).
AN2 Therapeutics recently announced a decision to voluntarily pause enrollment of the phase 3 portion of the phase 2/3 trial, EBO-301, in light of potentially lower than expected efficacy data obtained from the phase 2 trial.
Biora Therapeutics recently announced the initiation of phase 1 clinical trials of BT-600, a novel drug-device combination for ulcerative colitis (UC) patients.
MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a £7 million Series A financing round, led by Mercia Ventures.
Jane Kendrew changed paths after a year of her first degree knowing it was exactly the right way for her. She left university with a first class honours degree and turned down the offer of a PhD to start her dream job as a research scientist.
Novo Nordisk is set to acquire three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, has been awarded Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) by the United States Food and Drug Administration (FDA).
A bipartisan group of US lawmakers is urging the Biden administration to conduct a formal investigation and place sanctions against biotech firm WuXi AppTec, citing its connections to the Chinese military.
PrecisionLife has partnered with healthcare center the Metrodora Institute to jumpstart the diagnosis and treatment options for a range of chronic diseases including long COVID, ME/CFS, ALS and Sjögren's syndrome.
TILT Biotherapeutics, a clinical-stage biotech company developing cancer immunotherapies, has received a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project to treat ovarian cancer using its TILT-123 asset.
The US FDA has granted fast track designation to CAN-3110, a viral immunotherapy candidate from Candel Therapeutics to treat patients with recurrent high-grade glioma (HGG) and improve overall survival.
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.
Following positive advice from the Scottish Medicines Consortium (SMC), the first biologic treatment for inflammatory skin disease, hidradenitis suppurativa (HS), is now available in Scotland on the NHS.
Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.
Vicore Pharma has entered into an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku to commercialize Vicore’s idiopathic pulmonary fibrosis (IPF) drug candidate C21 in Japan.
Just – Evotec Biologics has expanded its relationship with Advanced BioScience Laboratories (ABL), a global CDMO serving the US Government and biopharmaceutical industry.
GSK’s vaccine Arexvy is currently undergoing regulatory review with the potential of being approved in Europe for use in adults aged between 50 and 59 who are at an increased risk for respiratory syncytial virus (RSV) infection.
Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry. Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.
In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gaining the first FDA approval for a CRISPR-based drug, exagamglogene autotemcel (Casgevy) for the treatment of sickle cell disease with vaso-occlusive crisis.
Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
Orano Med, a biotech firm developing targeted alpha therapies for oncology, has announced the launch of its ATLab (alpha therapy laboratory) in Onnaing, France.
Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has completed a pre-investigational new drug (pre-IND) meeting with the FDA for a phase 1/2 clinical trial of its cell therapy product, CTH-401 for the treatment...
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended epcoritamab (tepkinly), its treatment for adults with diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing blood cancer, whose cancer...
Upon hearing the phrase ‘cancer treatment’, the first word that can typically spring to mind is chemotherapy – a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.
